According to an article published in PLoSOne, researchers from IDIBAPS reconstitute a new nasal respiratory epithelium from mature stem cells of the nasal mucosa of both healthy and inflamed tissue. They have met their objectives by using a technique based in the exposure of primary culture cells to the air.
The World Health Organisation (WHO) has appointed Dr. Pedro Alonso as director of its Global Malaria Programme. Dr Alonso is currently director of the Barcelona Institute for Global Health (ISGlobal), Head of the International Health and Tropical Medicine Unit at the Hospital Clínic of Barcelona, and Professor at the University of Barcelona. He will take up his position at the WHO headquarters in Geneva in October. This appointment to one of the most important posts at the UN health agency is recognition of his work in the field of global health through ISGlobal.
Euroimmun acquires the rights of a patent developed by Dr. Graus and Dr. Dalmau for the diagnosis of autoimmune diseases
Dr. Graus and Dr. Dalmau have developed a technology for the diagnosis, prognosis and treatment of patients with an autoimmune disease associated to sleep disorders. It is based on detecting the presence of antibodies against the neuronal protein IGLON5 by immunocytochemistry of transfected cells.
The report named “Spanish Participation in the Innovative Medicines Initiative (IMI)” has been recently published by the Center for Industrial Technological Development (CDTI). This report lists the main indicators of participation in 8 of the 11 IMI’s calls supported under the 7th Framework Programme.
In the third edition of the Fellowship in Liver Transplant Surgery, Astellas Pharma has exclusively chosen the Liver Surgery and Transplantation Unit at the Hospital Clínic de Barcelona to train a specialist in this field. This year, Dr. Rocío García Pérez, a specialist in General and Digestive Surgery, has been awarded with the fellowship. Dr. Pérez started her formation on May 15th at the department led by Dr. Juan Carlos García-Valdecasas.
In the context of the Graphene Week 2014, the European Commission announced that the Graphene Flagship, one of the largest European research initiatives, is doubling its size and now includes more than 140 organizations from 23 countries. IDIBAPS is one of new 66 partners of the consortium through the team of Maria Victoria Sánchez-Vives, MD, PhD, ICREA Research Professor and team leader of the IDIBAPS group Systems Neuroscience. Professor Sanchez-Vives joins the Neurographene project, coordinated by Rosa Villa, PhD, from the CIBER-BBN Biomonitoring Group at the Barcelona Microelectronics Institute (IMB-CNM), and whose aim is to validate graphene as a brain interface material and to develop devices for both recording neural activity and for brain stimulation. The other partner in this project is the Austrian company Guger Technologies.